Related Experiment Video
Updated: Apr 19, 2026
In vitro Mesothelial Clearance Assay that Models the Early Steps of Ovarian Cancer Metastasis
Published on: February 17, 2012
In vitro chemoresponse in metachronous pairs of ovarian cancers
Heather J Dalton1, James V Fiorica2, Robert P Edwards3
1The University of Texas M. D. Anderson Cancer Center, Department of Gynecologic Oncology and Reproductive Medicine, Houston, TX, U.S.A.
Background/Aim:
An in vitro chemoresponse assay may aid effective therapy selection in epithelial ovarian cancer (EOC). This study explores changes in chemoresponse between paired primary and recurrent EOC tumors.
Patients And Methods:
RESULTS from metachronous tumors were examined in 242 patients. Changes in in vitro chemoresponse, measured by the area under the dose response curve (AUC) between paired tumors were assessed.
Results:
A significant increase in AUC was identified in most first-line therapies over time. No significant difference was observed in most recurrent therapies. When the elapsed time between occurrences was <17 months, no difference was observed for any recurrent therapies, and half of first-line therapies exhibited significant increases in AUC. When ≥17 months, all 7 therapies showed significant increases.
Conclusion:
These results suggest an increase in chemoresistance over time, which is more pronounced for first-line therapies. This is consistent with clinical observations and suggests the biologic concordance between assay results and response to chemotherapy.
